Evaluate safety, tolerability, pharmacokinetics (PK), and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD).
Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Dystrophy (FSHD): Safety, Tolerability, Pharmacokinetics, and Target Engagement.
CHDR
Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ, van Brummelen EMJ, Odueyungbo A, Thompson LA, Hage M, Badrising UA, Raines S, Tracewell WG, van Engelen B, Cadavid D, Groeneveld GJ
